{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"<p>Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing </p>","eudractNumber":null,"id":7907,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[{"name":"BRCA (BReast CAncer)","id":"mt_204"}],"nctNumber":"NCT04830709","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-13T13:30:32+01:00","shortTitle":"SCOUT-1","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -","eudractNumber":null,"id":11163,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:17:05+01:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE - <br />","eudractNumber":null,"id":8881,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-05-22T14:57:51+02:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Systematische Erfassung und Einbeziehung von Patientinnen:pr&#228;ferenzen* in individuelle Entscheidungsfindung und aggregierte Leitlinienempfehlungen","eudractNumber":null,"id":11462,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-07-30T13:14:32+02:00","shortTitle":"SEP-SDM-LL","therapeutical":false,"therapyLines":[]},{"active":true,"description":"An International Clinical Program for the diagnosis and Treatment of children, adolescents and young adults with ependymoma","eudractNumber":"2013-002766-39","id":2398,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT02265770","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2020-06-18T10:07:43+02:00","shortTitle":"SIOP Ependymoma II","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Eine internationale prospektive Studie zum klinischen Hochrisiko-Medulloblastom (HR-MB) bei Patienten, die &#228;lter als 3 Jahre sind","eudractNumber":"2018-004250-17","id":9623,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"MYC (c-MYC)","id":"mt_73"},{"name":"TP53","id":"mt_24"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-04-19T10:36:51+02:00","shortTitle":"SIOP High-Risk Medulloblastoma","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div><div>UMBRELLA Protocol SIOP-RTSG 2016 - Integrated research and guidelines for\nstandardized diagnostics and therapy of kidney tumours in children, adolescents\nand young adults&#160;<br /><div><br /></div><div>DRKS00011208</div></div></div>","eudractNumber":"2016-004180-39","id":7308,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-03-01T11:14:11+01:00","shortTitle":"SIOP-RTSG 2016 [UMBRELLA]","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Internationale, prospektive \"Umbrella\" Studie incl. einer randomisierten Phase III-Studie zur Frage der Nichtunterlegenheit von 3 Kursen Hochdosis-Chemotherapie verglichen mit fokaler Radiotherapie + Standard-Chemotherapie in der Konsolidierung nach einer konventionellen Induktions-Chemotherapie f&#252;r Kinder mit einem ATRT im Alter von 12 - 35 Monaten zum Zeitpunkt der Bestrahlung","eudractNumber":"2018-003335-29","id":4960,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"Others","id":"mt_8"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-07-22T09:45:21+02:00","shortTitle":"SIOPe ATRT-01","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Klinische Forschungsplattform zur Behandlung von Eierstock-, Eileiter-, prim&#228;rem Bauchfell- und Geb&#228;rmutterschleimhautkrebs und deren Folgen","eudractNumber":null,"id":7358,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":"NCT05129969","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-09T11:11:23+01:00","shortTitle":"SMARAGD","therapeutical":false,"therapyLines":[]},{"active":true,"description":"3 oder 5 Jahre Zusatzbehandlung mit Imatinib nach Operation eines GIST bei Patienten mit hohem R&#252;ckfallrisiko: eine randomisierte Phase III Studie der Scandinavian Sarcoma Group (SSG)","eudractNumber":"2014-000898-39","id":5513,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"gio4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"}],"mutations":[],"nctNumber":"NCT02413736","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2018-04-26T08:10:37+02:00","shortTitle":"SSGXXII","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]},"initialUrl":"/api/studies?lang=de&page=31&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p>Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing </p>\",\"name\":\"SCOUT-1\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7907\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -\",\"name\":\"SEATTLE\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11163\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE - <br />\",\"name\":\"SEATTLE\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8881\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Systematische Erfassung und Einbeziehung von Patientinnen:pr&#228;ferenzen* in individuelle Entscheidungsfindung und aggregierte Leitlinienempfehlungen\",\"name\":\"SEP-SDM-LL\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11462\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"An International Clinical Program for the diagnosis and Treatment of children, adolescents and young adults with ependymoma\",\"name\":\"SIOP Ependymoma II\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/2398\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Eine internationale prospektive Studie zum klinischen Hochrisiko-Medulloblastom (HR-MB) bei Patienten, die &#228;lter als 3 Jahre sind\",\"name\":\"SIOP High-Risk Medulloblastoma\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9623\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<div><div>UMBRELLA Protocol SIOP-RTSG 2016 - Integrated research and guidelines for\\nstandardized diagnostics and therapy of kidney tumours in children, adolescents\\nand young adults&#160;<br /><div><br /></div><div>DRKS00011208</div></div></div>\",\"name\":\"SIOP-RTSG 2016 [UMBRELLA]\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7308\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Internationale, prospektive \\\"Umbrella\\\" Studie incl. einer randomisierten Phase III-Studie zur Frage der Nichtunterlegenheit von 3 Kursen Hochdosis-Chemotherapie verglichen mit fokaler Radiotherapie + Standard-Chemotherapie in der Konsolidierung nach einer konventionellen Induktions-Chemotherapie f&#252;r Kinder mit einem ATRT im Alter von 12 - 35 Monaten zum Zeitpunkt der Bestrahlung\",\"name\":\"SIOPe ATRT-01\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/4960\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Klinische Forschungsplattform zur Behandlung von Eierstock-, Eileiter-, prim&#228;rem Bauchfell- und Geb&#228;rmutterschleimhautkrebs und deren Folgen\",\"name\":\"SMARAGD\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7358\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"3 oder 5 Jahre Zusatzbehandlung mit Imatinib nach Operation eines GIST bei Patienten mit hohem R&#252;ckfallrisiko: eine randomisierte Phase III Studie der Scandinavian Sarcoma Group (SSG)\",\"name\":\"SSGXXII\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/5513\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=32\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}